ReviewAnimal cells and systems2026
Natural killer T cells as therapeutic targets for neuroinflammatory disorders.
Review in Animal cells and systems, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural killer T (NKT) cells are innate-like T lymphocytes that express natural killer (NK) cell receptors (NKRs), which recognize glycolipid antigens presented by the MHC class I-like protein CD1d, linking innate and adaptive immunity. NKT cells include two main subsets, type I and type II, which differ in TCR usage and antigen specificity. In addition, NKT-like cells, which express NKRs but are CD1d-independent, have attracted growing interest in neuroimmunology. These NKR-expressing T cells play important roles in either promoting or suppressing pathological conditions within the brain. This review overviews recent advances in understanding NKT cells in immune disorders of the central nervous system (CNS), including neurodegenerative diseases, neuroinflammation, autoimmune diseases, brain injury, and CNS malignancies, such as glioblastoma. By interacting with CD1d on non-immune cells (e.g. astrocytes) and immune cells (e.g. microglia) through their TCR, type I NKT cells help maintain or disrupt immune homeostasis in the CNS. In addition, exogenous ligands, such as alpha-galactosylceramide, can modify type I and type II NKT cell phenotypes and promote regulatory functions in NKT-like cells, which may mitigate excessive inflammation. This review provides insights into how NKT cell subsets could serve as therapeutic targets for neuroinflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.